Cargando…

Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency

Naturally occurring adeno-associated virus (AAV) serotypes that bind to ligands such as AVB sepharose or heparin can be purified by affinity chromatography, which is a more efficient and scalable method than gradient ultracentrifugation. Wild type AAV8 does not bind effectively to either of these mo...

Descripción completa

Detalles Bibliográficos
Autores principales: van Lieshout, Laura P., Stegelmeier, Ashley A., Rindler, Tara N., Lawder, John J., Sorensen, Debra L., Frost, Kathy L., Booth, Stephanie A., Bridges, James P., Wootton, Sarah K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024426/
https://www.ncbi.nlm.nih.gov/pubmed/33028973
http://dx.doi.org/10.1038/s41434-020-00198-7
_version_ 1783675305978757120
author van Lieshout, Laura P.
Stegelmeier, Ashley A.
Rindler, Tara N.
Lawder, John J.
Sorensen, Debra L.
Frost, Kathy L.
Booth, Stephanie A.
Bridges, James P.
Wootton, Sarah K.
author_facet van Lieshout, Laura P.
Stegelmeier, Ashley A.
Rindler, Tara N.
Lawder, John J.
Sorensen, Debra L.
Frost, Kathy L.
Booth, Stephanie A.
Bridges, James P.
Wootton, Sarah K.
author_sort van Lieshout, Laura P.
collection PubMed
description Naturally occurring adeno-associated virus (AAV) serotypes that bind to ligands such as AVB sepharose or heparin can be purified by affinity chromatography, which is a more efficient and scalable method than gradient ultracentrifugation. Wild type AAV8 does not bind effectively to either of these molecules, which constitutes a barrier to using this vector when a high throughput design is required. Previously, AAV8 was engineered to contain a SPAKFA amino acid sequence to facilitate purification using AVB sepharose resin; however, in vivo studies were not conducted to examine whether these capsid mutations altered the transduction profile. To address this gap in knowledge, a mutant AAV8 capsid was engineered to bind to AVB sepharose and heparan sulfate (AAV8-AVB-HS), which efficiently bound to both affinity columns, resulting in elution yields of >80% of the total vector loaded compared to <5% for wild type AAV8. However, in vivo comparison by intramuscular, intravenous, and intraperitoneal vector administration demonstrated a significant decrease in AAV8-AVB-HS transduction efficiency without alteration of the transduction profile. Therefore, although it is possible to engineer AAV capsids to bind various affinity ligands, the consequences associated with mutating surface exposed residues have the potential to negatively impact other vector characteristics including in vivo potency and production yield. This study demonstrates the importance of evaluating all aspects of vector performance when engineering AAV capsids.
format Online
Article
Text
id pubmed-8024426
institution National Center for Biotechnology Information
language English
publishDate 2023
record_format MEDLINE/PubMed
spelling pubmed-80244262022-04-07 Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency van Lieshout, Laura P. Stegelmeier, Ashley A. Rindler, Tara N. Lawder, John J. Sorensen, Debra L. Frost, Kathy L. Booth, Stephanie A. Bridges, James P. Wootton, Sarah K. Gene Ther Article Naturally occurring adeno-associated virus (AAV) serotypes that bind to ligands such as AVB sepharose or heparin can be purified by affinity chromatography, which is a more efficient and scalable method than gradient ultracentrifugation. Wild type AAV8 does not bind effectively to either of these molecules, which constitutes a barrier to using this vector when a high throughput design is required. Previously, AAV8 was engineered to contain a SPAKFA amino acid sequence to facilitate purification using AVB sepharose resin; however, in vivo studies were not conducted to examine whether these capsid mutations altered the transduction profile. To address this gap in knowledge, a mutant AAV8 capsid was engineered to bind to AVB sepharose and heparan sulfate (AAV8-AVB-HS), which efficiently bound to both affinity columns, resulting in elution yields of >80% of the total vector loaded compared to <5% for wild type AAV8. However, in vivo comparison by intramuscular, intravenous, and intraperitoneal vector administration demonstrated a significant decrease in AAV8-AVB-HS transduction efficiency without alteration of the transduction profile. Therefore, although it is possible to engineer AAV capsids to bind various affinity ligands, the consequences associated with mutating surface exposed residues have the potential to negatively impact other vector characteristics including in vivo potency and production yield. This study demonstrates the importance of evaluating all aspects of vector performance when engineering AAV capsids. 2023-04 2020-10-07 /pmc/articles/PMC8024426/ /pubmed/33028973 http://dx.doi.org/10.1038/s41434-020-00198-7 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
van Lieshout, Laura P.
Stegelmeier, Ashley A.
Rindler, Tara N.
Lawder, John J.
Sorensen, Debra L.
Frost, Kathy L.
Booth, Stephanie A.
Bridges, James P.
Wootton, Sarah K.
Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency
title Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency
title_full Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency
title_fullStr Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency
title_full_unstemmed Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency
title_short Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency
title_sort engineered aav8 capsid acquires heparin and avb sepharose binding capacity but has altered in vivo transduction efficiency
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024426/
https://www.ncbi.nlm.nih.gov/pubmed/33028973
http://dx.doi.org/10.1038/s41434-020-00198-7
work_keys_str_mv AT vanlieshoutlaurap engineeredaav8capsidacquiresheparinandavbsepharosebindingcapacitybuthasalteredinvivotransductionefficiency
AT stegelmeierashleya engineeredaav8capsidacquiresheparinandavbsepharosebindingcapacitybuthasalteredinvivotransductionefficiency
AT rindlertaran engineeredaav8capsidacquiresheparinandavbsepharosebindingcapacitybuthasalteredinvivotransductionefficiency
AT lawderjohnj engineeredaav8capsidacquiresheparinandavbsepharosebindingcapacitybuthasalteredinvivotransductionefficiency
AT sorensendebral engineeredaav8capsidacquiresheparinandavbsepharosebindingcapacitybuthasalteredinvivotransductionefficiency
AT frostkathyl engineeredaav8capsidacquiresheparinandavbsepharosebindingcapacitybuthasalteredinvivotransductionefficiency
AT boothstephaniea engineeredaav8capsidacquiresheparinandavbsepharosebindingcapacitybuthasalteredinvivotransductionefficiency
AT bridgesjamesp engineeredaav8capsidacquiresheparinandavbsepharosebindingcapacitybuthasalteredinvivotransductionefficiency
AT woottonsarahk engineeredaav8capsidacquiresheparinandavbsepharosebindingcapacitybuthasalteredinvivotransductionefficiency